Sagespring Wealth Partners LLC Acquires New Position in DexCom, Inc. (NASDAQ:DXCM)

Sagespring Wealth Partners LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,380 shares of the medical device company's stock, valued at approximately $418,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Geode Capital Management LLC grew its position in DexCom by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after purchasing an additional 56,094 shares during the period. Jennison Associates LLC grew its holdings in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after acquiring an additional 710,858 shares during the period. Norges Bank purchased a new stake in DexCom during the fourth quarter valued at $385,367,000. Charles Schwab Investment Management Inc. boosted its position in DexCom by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after purchasing an additional 91,051 shares during the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in shares of DexCom by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock valued at $144,152,000 after purchasing an additional 201,181 shares during the period. Institutional investors own 97.75% of the company's stock.

DexCom Stock Down 0.2 %

Shares of DexCom stock traded down $0.14 during trading on Friday, reaching $68.59. The company's stock had a trading volume of 3,702,730 shares, compared to its average volume of 4,222,362. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $139.24. The company has a 50-day simple moving average of $74.98 and a two-hundred day simple moving average of $76.67. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $26.90 billion, a price-to-earnings ratio of 47.97, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on DXCM shares. Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Finally, Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.